Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 4,400 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $13.47, for a total value of $59,268.00. Following the completion of the transaction, the chief executive officer now directly owns 737,767 shares of the company’s stock, valued at $9,937,721.49. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded up $0.10 during trading on Tuesday, reaching $13.55. The company had a trading volume of 155,300 shares, compared to its average volume of 235,437. Atara Biotherapeutics, Inc. has a twelve month low of $11.80 and a twelve month high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). equities analysts anticipate that Atara Biotherapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/11/14/insider-selling-atara-biotherapeutics-inc-atra-ceo-sells-4400-shares-of-stock.html.

A number of institutional investors have recently modified their holdings of ATRA. Bank of New York Mellon Corp increased its position in Atara Biotherapeutics by 5.3% in the 1st quarter. Bank of New York Mellon Corp now owns 120,097 shares of the biotechnology company’s stock valued at $2,468,000 after buying an additional 6,069 shares in the last quarter. Swiss National Bank increased its position in Atara Biotherapeutics by 9.6% in the 1st quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 2,500 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in Atara Biotherapeutics by 62.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock valued at $522,000 after buying an additional 9,774 shares in the last quarter. American International Group Inc. increased its position in Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Atara Biotherapeutics by 10.9% in the 1st quarter. Vanguard Group Inc. now owns 831,925 shares of the biotechnology company’s stock valued at $17,095,000 after buying an additional 81,634 shares in the last quarter. 82.95% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on ATRA shares. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $20.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $24.40.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply